BR112016026559A8 - uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit - Google Patents
uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kitInfo
- Publication number
- BR112016026559A8 BR112016026559A8 BR112016026559A BR112016026559A BR112016026559A8 BR 112016026559 A8 BR112016026559 A8 BR 112016026559A8 BR 112016026559 A BR112016026559 A BR 112016026559A BR 112016026559 A BR112016026559 A BR 112016026559A BR 112016026559 A8 BR112016026559 A8 BR 112016026559A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- anticancer agent
- combination
- lung cancer
- chemotherapy
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title abstract 4
- 238000002512 chemotherapy Methods 0.000 title abstract 2
- 229910052697 platinum Inorganic materials 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 3
- 201000005202 lung cancer Diseases 0.000 abstract 3
- 208000020816 lung neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000005911 anti-cytotoxic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229960000397 bevacizumab Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 1
- 101710135378 pH 6 antigen Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
tratamento de câncer de pulmão usando uma combinação de um anticorpo anti-pd-1 e outro agente anticâncer. esta descrição fornece um método para tratar um indivíduo afligido com um câncer de pulmão, cujo método compreende administrar ao indivíduo quantidades terapeuticamente efetivas de: (a) um agente anticâncer, que é um anticorpo ou uma porção de ligação de antígeno do mesmo que especificamente liga-se a um receptor de morte programada-1 (pd-1) e inibe a atividade de pd-1; e (b) outro agente anticâncer. o outro agente anticâncer pode ser uma quimioterapia de dubleto com base em platina, um inibidor de tirosina cinase alvejado por egfr, bevacizumabe, um anticorpo de antígeno-4 de t-linfócito anticitotóxico (ctla-4), ou qualquer outra terapia usada para tratar o câncer de pulmão na técnica ou descrita aqui.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461993917P | 2014-05-15 | 2014-05-15 | |
US201462005640P | 2014-05-30 | 2014-05-30 | |
US201562152669P | 2015-04-24 | 2015-04-24 | |
PCT/US2015/031241 WO2015176033A1 (en) | 2014-05-15 | 2015-05-15 | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016026559A2 BR112016026559A2 (pt) | 2017-08-15 |
BR112016026559A8 true BR112016026559A8 (pt) | 2021-07-13 |
Family
ID=53276304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016026559A BR112016026559A8 (pt) | 2014-05-15 | 2015-05-15 | uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit |
Country Status (10)
Country | Link |
---|---|
US (3) | US20170158776A1 (pt) |
EP (2) | EP3142697A1 (pt) |
JP (1) | JP2017515859A (pt) |
KR (2) | KR20230144099A (pt) |
CN (2) | CN106714839A (pt) |
BR (1) | BR112016026559A8 (pt) |
CA (1) | CA2949121A1 (pt) |
MX (2) | MX2016014753A (pt) |
RU (1) | RU2695332C2 (pt) |
WO (1) | WO2015176033A1 (pt) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
KR20240017102A (ko) | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
ES2899457T3 (es) | 2014-02-04 | 2022-03-11 | Pfizer | Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer |
WO2015166986A1 (ja) | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
AU2015355137A1 (en) * | 2014-12-02 | 2017-06-08 | Celgene Corporation | Combination therapies |
CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
KR20170140316A (ko) | 2015-04-28 | 2017-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료 |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
EP3303401A4 (en) * | 2015-06-01 | 2018-12-26 | The University of Chicago | Treatment of cancer by manipulation of commensal microflora |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
KR20180018538A (ko) | 2015-06-17 | 2018-02-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
PT3328419T (pt) | 2015-07-30 | 2021-11-26 | Macrogenics Inc | Moléculas de ligação pd-1 e métodos de utilização |
SG10201914109VA (en) | 2015-08-11 | 2020-02-27 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
US20180231554A1 (en) * | 2015-09-04 | 2018-08-16 | The Brigham And Women's Hospital, Inc. | Programmed cell death (pd-1) inhibitor therapy for patients with pd-1-expressing cancers |
EP3377534A1 (en) | 2015-11-18 | 2018-09-26 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody |
ES2823279T3 (es) * | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab |
SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
US10358496B2 (en) | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
US11209441B2 (en) | 2016-04-05 | 2021-12-28 | Bristol-Myers Squibb Company | Cytokine profiling analysis |
WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
US11285285B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment |
TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
EP3463456A1 (en) * | 2016-06-03 | 2019-04-10 | ImClone LLC | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
KR20190019121A (ko) * | 2016-06-17 | 2019-02-26 | 오사카 유니버시티 | 종양 내 정맥 형성 촉진제 |
CA3026588A1 (en) * | 2016-07-01 | 2018-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
WO2018057303A1 (en) | 2016-09-26 | 2018-03-29 | Imclone Llc | Combination therapy for cancer |
JP2019530704A (ja) | 2016-10-06 | 2019-10-24 | ファイザー・インコーポレイテッド | がんの処置のためのアベルマブの投与レジメン |
KR20240023677A (ko) | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
MA50948A (fr) * | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
JP2020502149A (ja) * | 2016-12-15 | 2020-01-23 | プロゲン・ピージー500・シリーズ・プロプライエタリー・リミテッドProgen Pg500 Series Pty Ltd | 組成物およびその使用 |
CN116884477A (zh) | 2017-01-05 | 2023-10-13 | 佰欧迪塞克斯公司 | 用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法 |
EP3583113A4 (en) * | 2017-02-17 | 2020-08-26 | George Todaro | USE OF TGF-ALPHA FOR TREATMENT OF DISEASES AND DISORDERS |
CA3054289A1 (en) * | 2017-02-21 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
CN110799231B (zh) | 2017-05-19 | 2022-08-02 | 精呼吸股份有限公司 | 干粉输送装置及其使用方法 |
EP3630842A2 (en) * | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
WO2019023786A1 (en) * | 2017-08-01 | 2019-02-07 | University Health Network | COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE |
TWI798243B (zh) * | 2017-08-08 | 2023-04-11 | 昇捷生物科技股份有限公司 | 治療癌症的方法 |
AU2018327339B2 (en) * | 2017-09-08 | 2023-10-12 | Promontory Therapeutics Inc. | Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof |
CN111386117A (zh) * | 2017-09-29 | 2020-07-07 | 百时美施贵宝公司 | 治疗癌症的组合物和方法 |
WO2019071008A1 (en) | 2017-10-04 | 2019-04-11 | Pneuma Respiratory, Inc. | ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE |
WO2019079461A1 (en) | 2017-10-17 | 2019-04-25 | Pneuma Respiratory, Inc. | NASAL MEDICATION DELIVERY APPARATUS AND METHODS OF USE |
CA3082192A1 (en) | 2017-11-08 | 2019-05-16 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
JP2021510108A (ja) * | 2018-01-08 | 2021-04-15 | ニューマ・リスパイラトリー・インコーポレイテッド | 呼吸により電気的に作動する液滴送達装置を使用した肺癌の治療 |
KR102089241B1 (ko) * | 2018-02-05 | 2020-03-16 | 한국과학기술원 | 암 환자에서 면역 치료 효과를 예측하는 방법 |
AU2019288048B2 (en) * | 2018-06-20 | 2022-08-11 | Fujifilm Corporation | Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade |
AU2019305637A1 (en) * | 2018-07-18 | 2021-03-11 | Genentech, Inc. | Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent |
JP2022505647A (ja) * | 2018-10-23 | 2022-01-14 | ブリストル-マイヤーズ スクイブ カンパニー | 腫瘍の処置方法 |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | ***新抗原及其用途 |
CN111617243B (zh) * | 2019-02-28 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
CN113747947A (zh) * | 2019-02-28 | 2021-12-03 | 沙塔克实验室有限公司 | 组合疗法 |
WO2020186149A1 (en) * | 2019-03-13 | 2020-09-17 | The Brigham And Women's Hospital, Inc. | Targeting regulatory b cells and their regulators for cancer immunotherapy |
CN113631189A (zh) * | 2019-03-13 | 2021-11-09 | 默沙东公司 | 包含ctla-4和pd-1封闭剂的抗癌联合治疗 |
WO2020198510A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
MA55508A (fr) * | 2019-03-29 | 2022-02-09 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
WO2020257745A1 (en) * | 2019-06-21 | 2020-12-24 | University Of Kansas | Compositions and methods useful in treating brain diseases |
CN115087461A (zh) * | 2019-12-20 | 2022-09-20 | 默沙东有限责任公司 | 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法 |
WO2022006514A1 (en) * | 2020-07-02 | 2022-01-06 | Gopath Laboratories Llc | Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer |
US11793945B2 (en) | 2021-06-22 | 2023-10-24 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
US20230322928A1 (en) * | 2022-03-07 | 2023-10-12 | Medimmune, Llc | Treatment methods using ctla-4 and pd-1 bispecific antibodies |
WO2024002074A1 (zh) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
WO2024040175A1 (en) | 2022-08-18 | 2024-02-22 | Pulmatrix Operating Company, Inc. | Methods for treating cancer using inhaled angiogenesis inhibitor |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA209003A (en) | 1921-03-01 | Krogman Joseph | Whiffletree connector | |
CA209004A (en) | 1921-03-01 | K. Kronlund Theodore | Mattress | |
CA209012A (en) | 1921-03-01 | L. Lilly Thomas | End gates for autotrucks | |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
CA2361553A1 (en) | 1999-01-29 | 2000-08-03 | Zhenping Zhu | Antibodies specific to kdr and uses thereof |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート,エルエルシー | Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用 |
CA2478169C (en) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
EP2377555A3 (en) | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
WO2009060198A1 (en) | 2007-11-09 | 2009-05-14 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
PE20120341A1 (es) * | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
EP2710137B1 (en) | 2011-03-10 | 2018-09-19 | Provectus Pharmatech, Inc. | A combination of rose bengal and anti-ctla4 antibody for use in the treatment of cancer |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
AU2012288413B2 (en) | 2011-07-24 | 2016-10-13 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
-
2015
- 2015-05-15 RU RU2016148927A patent/RU2695332C2/ru active
- 2015-05-15 CN CN201580038308.8A patent/CN106714839A/zh active Pending
- 2015-05-15 EP EP15726468.0A patent/EP3142697A1/en not_active Ceased
- 2015-05-15 WO PCT/US2015/031241 patent/WO2015176033A1/en active Application Filing
- 2015-05-15 JP JP2016567719A patent/JP2017515859A/ja active Pending
- 2015-05-15 KR KR1020237032702A patent/KR20230144099A/ko not_active Application Discontinuation
- 2015-05-15 CN CN202211265390.6A patent/CN115590953A/zh active Pending
- 2015-05-15 CA CA2949121A patent/CA2949121A1/en active Pending
- 2015-05-15 KR KR1020167035139A patent/KR20170003692A/ko not_active IP Right Cessation
- 2015-05-15 EP EP20178309.9A patent/EP3760229A3/en active Pending
- 2015-05-15 US US15/311,409 patent/US20170158776A1/en not_active Abandoned
- 2015-05-15 MX MX2016014753A patent/MX2016014753A/es unknown
- 2015-05-15 BR BR112016026559A patent/BR112016026559A8/pt active Search and Examination
-
2016
- 2016-11-10 MX MX2022004000A patent/MX2022004000A/es unknown
-
2018
- 2018-06-29 US US16/024,376 patent/US20180319892A1/en not_active Abandoned
-
2021
- 2021-01-21 US US17/248,367 patent/US20210324106A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3760229A2 (en) | 2021-01-06 |
CN106714839A (zh) | 2017-05-24 |
KR20230144099A (ko) | 2023-10-13 |
CA2949121A1 (en) | 2015-11-19 |
BR112016026559A2 (pt) | 2017-08-15 |
RU2695332C2 (ru) | 2019-07-23 |
WO2015176033A1 (en) | 2015-11-19 |
CN115590953A (zh) | 2023-01-13 |
US20170158776A1 (en) | 2017-06-08 |
RU2016148927A3 (pt) | 2019-01-10 |
MX2016014753A (es) | 2017-03-06 |
KR20170003692A (ko) | 2017-01-09 |
MX2022004000A (es) | 2022-04-26 |
EP3142697A1 (en) | 2017-03-22 |
EP3760229A3 (en) | 2021-04-07 |
US20180319892A1 (en) | 2018-11-08 |
JP2017515859A (ja) | 2017-06-15 |
RU2016148927A (ru) | 2018-06-18 |
US20210324106A1 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016026559A8 (pt) | uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit | |
CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
MX2021008053A (es) | Metodos para monitorear y terapias para usarse en tratar el cancer. | |
PH12017502270A1 (en) | Combination therapy for the treatment of cancer | |
EP3572430A3 (en) | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent | |
CL2019002850A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3. | |
MX2018014950A (es) | Terapia de combinacion. | |
BR112017021688A2 (pt) | composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo | |
BR112017006825A2 (pt) | anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização | |
AR107442A1 (es) | Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer | |
BR112018006257A2 (pt) | anticorpos anti-pd-1 e composições | |
BR112018002274A2 (pt) | anticorpos anti-pd-1 | |
BR112016017256A2 (pt) | combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer | |
BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
MX2017013178A (es) | Terapia de combinacion para cancer. | |
BR112016016699A2 (pt) | Anticorpos humanos para pd-1 | |
BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
BR112017018872A2 (pt) | combinação de um antagonista pd-1 e eribulina para tratamento de câncer | |
BR112019004185A2 (pt) | combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos | |
UY35136A (es) | Métodos para tratar el cáncer de ovario con antagonistas de dll4. | |
MX2019011657A (es) | Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer. | |
BR112016023025A2 (pt) | direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |